Monday, April 04, 2022

Onconova Therapeutics (ONTX)
Narazaciclib Data Presented At Scientific Industry Conference

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Onconova Presented Data At The Next Generation Kinase Inhibitors Summit.  Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information in greater detail than a medical meeting would typically allow. The communication with other scientists in the field also helps to establish a company's expertise, and can lead to future collaborations, clinical site participation, and corporate partnerships.

Data Gave An Overview and Summary of Narazaciclib.  Data was presented by Onconova's Director of Corporate Development, and a session was chaired by Onconova's CEO. These presentations gave data on narazaciclib's activity against CDK4, CDK6, and other intermediaries in a pathway that leads to cancer cell growth, proliferation, and metastasis. The data showed potent inhibition consistent with the ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.